Program
SHR-2173
A development code. Also written as “SHR-2173 injection” and “SHR-2173 Injection”.
In Jiangsu HengRui Medicine's pipeline, IFNAR1/TACI
. Its studies are mostly in Lupus Erythematosus, Systemic · Myasthenia Gravis · Purpura, Thrombocytopenic, Idiopathic · Glomerulonephritis, IGA · Glomerulonephritis, Membranous, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 86 open or running | phase 2since Nov 13, 2025 | Apr 8, 2025 | Apr 2027phase 2 · NCT07354932 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
SHR-2173
, phase 3, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 8, 2025First study: phase 1 study in Lupus Erythematosus, SystemicFirst studyNCT06955598 · 30 enrolled · China
- May 15, 2025Phase 1 study in Healthy VolunteersNCT06995001 · 35 enrolled · China
- Sep 26, 2025Phase 1 study in Purpura, Thrombocytopenic, IdiopathicNCT07206758 · 10 planned · China
- Nov 13, 20253 phase 2 studiesNCT07229742, NCT07289763, NCT07299422
- Jan 12, 2026Phase 2 study in Glomerulonephritis, IGANCT07354932 · 84 planned · China
- May 20, 2026Phase 2 study in Myasthenia GravisNCT07622342 · 60 planned · China
Ahead
- Apr 2027Primary completion: phase 2 study in Glomerulonephritis, IGANCT07354932
- Jun 2027Primary completion: phase 2 study in Active Lupus NephritisNCT07229742
- Aug 2027Primary completion: phase 2 study in Primary Membranous NephropathyNCT07289763
- Sep 2027Primary completion: phase 2 study in Myasthenia GravisNCT07622342
TargetBeta
“IFNAR1/TACI”the company's pipeline, read by Claude · source
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07622342Myasthenia Gravis · China | 2 | Recruiting | Sep 2027 | 60 |
| NCT07354932Glomerulonephritis, IGA · China | 2 | Recruiting | Apr 2027 | 84 |
| NCT07299422Lupus Erythematosus, Systemic · China | 2 | Recruiting | Mar 2028 | 248 |
| NCT07289763Primary Membranous Nephropathy · China | 2 | Recruiting | Aug 2027 | 75 |
| NCT07229742Active Lupus Nephritis · China | 2 | Recruiting | Jun 2027 | 51 |
| NCT07206758Purpura, Thrombocytopenic, Idiopathic · China | 1 | Recruiting | Jun 2026 | 10 |
| NCT06995001Healthy Volunteers · China | 1 | Completed | Nov 28, 2024 | 35 |
| NCT06955598Lupus Erythematosus, Systemic · China | 1 | Completed | Nov 10, 2025 | 30 |
How it is read
Names in the registry
- “SHR-2173 injection”, 8 entries
- “SHR-2173 Injection”, 3 entries
- “SHR-2173”, 2 entries
Codes read as this program: SHR2173.
Conditions, from the studies’ own filings
- Lupus Erythematosus, Systemic, 2 studies
- Myasthenia Gravis, 1 study
- Purpura, Thrombocytopenic, Idiopathic, 1 study
- Glomerulonephritis, IGA, 1 study
- Glomerulonephritis, Membranous, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.